key: cord-0748530-dhwwhsgb
authors: Schnaubelt, Sebastian; Breyer, Marie-Kathrin; Siller-Matula, Jolanta; Domanovits, Hans
title: Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report
date: 2020-06-24
journal: Eur Heart J Case Rep
DOI: 10.1093/ehjcr/ytaa166
sha: d801a0c9a56ac71d6d0b18b058edb07ef4fea038
doc_id: 748530
cord_uid: dhwwhsgb

BACKGROUND: Fulminant cardiac involvement in COVID-19 patients has been reported; the underlying suspected mechanisms include myocarditis, arrhythmia, and cardiac tamponade. In parallel, atrial fibrillation is common in the elderly population which is at particularly high risk for COVID-19 morbidity and mortality. CASE SUMMARY: A 72-year-old male SARS-CoV2-positive patient was admitted to the intensive care unit due to delirium and acute respiratory failure. Atrial fibrillation known from history was exacerbated, and made complex rate and rhythm control necessary. Progressive heart failure with haemodynamic deterioration and acute kidney injury with the need for continuous renal replacement therapy were further aggravated by pericardial tamponade. DISCUSSION: Treatment of acute heart failure in COVID-19 patients with a cytokine storm complicated by tachycardic atrial fibrillation should include adequate rate or rhythm control, and potentially immunomodulation.

Coronavirus disease (COVID)-19 is an emerging pandemic manifesting from asymptomatic infection to acute respiratory distress syndrome (ARDS) and multiorgan failure. 1 Various phenotypes have been described, including a procoagulatory state, acute kidney injury (AKI), or hyperinflammatory syndromes such as a cytokine storm. 2, 3 Myocardial involvement is a common finding in critically ill patients, the aetiology being coronary microvascular ischaemia, stress cardiomyopathy, or sometimes viral myocarditis. 4 We report on an elderly male COVID-19 patient presenting with ARDS and fulminant heart failure aggravated by atrial fibrillation (AF) with fatal outcome.

• Atrial fibrillation might pose an additional risk factor for unfavourable outcome in COVID-19 patients.

• Consider continuous cardio-selective beta-blockers in COVID-19 patients with supraventricular, non-compensatory tachycardia. 

Case presentation

After having developed fever and fatigue, a 72-year-old male patient (body mass index 29.2) was diagnosed with COVID-19 and put in quarantine at home. Clinical worsening resulted in delirium. After 6 days, emergency medical services found the patient severely hypoxic (SpO 2 65%) despite his not complaining about dyspnoea. Oxygen was administered and the patient was transported to a designated COVID-19 pulmonary intensive care unit (ICU). History revealed a non-insulin-dependent diabetes mellitus type 2 (recent Hba1c 6.4%), aortic dissection type B (stable over time in various CTs), persistent AF, a smoking history (cessation 20 years ago), and chronic obstructive sleep apnoea syndrome (no therapy). Chronic medication consisted of apixaban (5 mg twice daily), gabapentin (150 mg twice daily), bisoprolol (5 mg twice daily), and metformin (500 mg twice daily), and did not include angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Upon arrival, the patient was normotensive with an irregular heart rhythm, appearing exhausted and perspiring, but not subjectively dyspnoeic. Auscultation revealed bilateral medium to coarse crackle sounds. He was intubated due to severe hypoxaemia [Horovitz index 111, positive end-expiratory pressure (PEEP) 18 cmH 2 A chest X-ray showed bilateral consolidations compatible with ARDS ( Figure 2) . Laboratory results showed AKI. Continuous renal replacement therapy (CRRT) was established and upgraded with an immunoadsorbant filter (Cytosorb V R ) for 48 h to counteract a suspected cytokine storm mirrored by rising interleukin-6 (IL-6) levels. The initial pro-brain natriuretic peptide (BNP) was 1612 ng/L, ultimately reaching 10-fold levels. High sensitivity troponin T (hs-TnT) values were undulant during the entire stay, with maximum levels of 200 ng/L. For the development of laboratory values over time, see Figure 3 . Due to organizational reasons and potential cardiac side effects, it was chosen not to administer experimental therapeutics such as hydroxychloroquine, tocilizumab, or antiviral agents.

More frequent tachycardic AF episodes did not respond to electrical cardioversion, escalation of landiolol (up to 40 lg/kg/min without effect of further escalation), or addition of amiodarone (300 mg in 30 min and 38 mg/h over 24 h thereafter). Also, digitoxin (0.25 mg daily) and ivabradine (5 mg twice daily)-initially showing promising results-ultimately proved ineffective. Progressing heart failure seemed to be mainly dependent on tachycardic AF. Levosimendan (10 lg/kg/min for 10 min and 0.2 lg/kg/min for 24 h thereafter) led to a transient positive effect that only lasted 24 h. In echocardiographic controls, pericardial effusion (circumference, 2-3 cm, Figure 4 ) developed in 48 h, leading to pericardial tamponade that was successfully drained (a SARS-CoV-2 test from the fluid was negative). After pericardiocentesis, haemodynamics improved only transiently, and LVSF/EF deteriorated rapidly. At this stage, an ultima ratio treatment option would have been veno-arterial extracorporeal membrane oxygenation (VA-ECMO). However, existing literature surrounding the role of VA-ECMO in the treatment of COVID-19-associated cardiogenic shock is scarce. Due to the multiple comorbidities, resource availability, and the perceived risk-benefit ratio, a decision against ECMO was made. In a multidisciplinary way, a do not resuscitate order was agreed on. Nine days after ICU admission, the patient died from multiorgan failure. Figure 5 gives an overview of the entire case.

Cardiac (co-)injury has already been duly noted as a crucial possible COVID-19 characteristic: most reports include perimyocarditis and de novo or aggravated heart failure. 5 Pericardial effusion or tamponade appear in up to 5% of cases. [6] [7] [8] In our patient, perimyocarditis and pericardial effusion might have been triggered by the underlying mechanisms ranging from potential direct viral invasion of the myocardium 9 and angiotensine-converting enzyme 2 signal pathways to a cytokine storm. 2, 5, 10 With extreme levels of IL-6, a state of virally driven hyperinflammation can be suspected in our case. In the final disease stage, the reported patient was positive for secondary haemophagocytic lymphohistiocytosis (sHLH) as suggested by Mehta et al. 2, 11 After discontinuation of immunoadsorption, IL-6 values exacerbated, strengthening this theory. In future similar cases, the IL-6 antibody tocilizumab could be a therapeutic option, if available.

The arrhythmogenic effect of COVID-19 might still be underreported and was noted in up to 17% of patients; the literature still lacks more precise differentiation. 5 Importantly, the presence of AF together with inadequate rate control might have a negative impact on patients' prognosis. With a large prevalence of AF in the general, and especially the elderly, population 12 and the known connection of arrhythmic burden and viral disease, 13 AF may influence mortality. While there may or may not be a direct causal relationship between AF and COVID-19, the often-needed extensive catecholamine support can either initiate or aggravate AF, therefore inducing a vicious circle of cardiac injury through tachyarrhythmogenic and adrenergic stress. 4,5,10 A possible treatment add-on in this dilemma would be milrinone, a synthetic non-catecholamine phosphodiesterase type III inhibitor. When compared with dobutamine, milrinone is associated with less tachycardia and increases the cardiac index, but reduces arterial blood pressure and pulmonary vascular resistance (the reason why it is often combined with noradrenaline and vasopressin). 14 Such an approach might represent an alternative in cardiogenic shock with a high ventricular rate.

Besides management of respiratory complications, comorbidities of COVID-19 patients are known to be important risk factors for worse outcome 5 -and AF should be recognized as one of them. In patients with tachyarrhythmia, short-acting cardioselective beta- blockers may be a good initial choice for heart rate control. Frequent reassessment of cardiac function by echocardiography will help to adapt treatment and to recognize complications in the course of the disease.

Treatment of acute heart failure in COVID-19 patients with a cytokine storm complicated by tachycardic AF should include adequate rate or rhythm control, and potentially immunomodulation. 

We thank Professor Dr Anton Laggner, Professor Dr Sylvia Hartl, and the physician and nursing staff of the pulmonary ICU for their support.

The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patient's guardians in line with COPE guidance. Conflicts of interest: none declared. 

Clinical course and mortality risk of severe COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

High-sensitivity cardiac troponin can be an ally in the fight against COVID-19

Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

The clinical and chest CT features associated with severe and critical COVID-19 pneumonia

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

COVID-19, ACE2, and the cardiovascular consequences

COVID-19 in the heart and the lungs: could we 'Notch' the inflammatory storm?

ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Cardiac and arrhythmic complications in Covid-19 patients

Current status of inotropes in heart failure